Steris Q2 profit beats expectations on healthcare strength

Reuters11-06
Steris <a href="https://laohu8.com/S/QTWO">Q2</a> profit beats expectations on healthcare strength 

Overview

  • Steris fiscal Q2 revenue grows 10%

  • Adjusted EPS for fiscal Q2 exceeds analyst estimates

  • Company raises fiscal 2026 outlook for organic revenue and adjusted EPS

Outlook

  • Company raises fiscal 2026 constant currency organic revenue growth to 7-8%

  • STERIS expects fiscal 2026 adjusted EPS to be $10.15-$10.30

  • Company anticipates fiscal 2026 free cash flow of approximately $850 mln

Result Drivers

  • HEALTHCARE SEGMENT - Healthcare revenue grew 9% driven by service and consumable sales, offset by tariff costs and inflation

  • APPLIED STERILIZATION TECHNOLOGIES - AST revenue rose 10% with growth in service revenue despite a decline in capital equipment sales

  • LIFE SCIENCES SEGMENT - Life Sciences revenue increased 13%, led by 39% growth in capital equipment sales

Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q2 Adjusted EPS

Beat

$2.47

$2.35 (8 Analysts)

Q2 Adjusted Net Income

Beat

$244.50 mln

$230.96 mln (5 Analysts)

Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

  • Wall Street's median 12-month price target for STERIS plc is $280.00, about 13.6% above its November 4 closing price of $241.85

Press Release: ID:nGNX1YFQr5

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment